Table 2 Comparisons between paraneoplastic anti-NMDARE and anti-NMDARE groups without teratoma

Total

159

12 (7.5%)

147 (92.5%)

–

Age, years, median (range)

25(9–78)

21 (17–43)

26 (9–78)

0.445^b

Sex (female)

89(56.0%)

11 (91.7%)

78 (53.1%)

0.01^a

Psychiatric symptoms

151 (95%)

11 (91.7%)

140 (95.2%)

0.474^c

Seizure

130 (81.8%)

12 (100%)

118 (80.3%)

0.125^c

Speech disturbances

60/141(42.6%)

5/11 (45.6%)

55/130 (42.3%)

1^c

Dyskinesias and movement disorders

90 (56.6%)

9 (75%)

81 (55.1%)

0.384^a

Autonomic instability

53 (33.3%)

6 (50%)

47 (32.0%)

0.53^c

Memory deficits

97/119 (81.5%)

6/8 (75.0%)

91/111 (82.0%)

0.64^c

Decreased consciousness

97 (61.0%)

10 (83.3%)

87 (59.2%)

0.129^c

Central hypoventilation

33 (20.8%)

8 (66.7%)

25 (17.0%)

< 0.001^c

Complications

106 (66.7%)

10 (83.3%)

96 (65.3%)

0.34^c

Abnormal MRI findings

61/148 (41.2%)

5/11 (45.5%)

56/137 (40.9%)

0.761^c

Abnormal EEG findings

113/137 (82.5%)

11/12 (91.6%)

102/125 (81.6%)

1^c

Abnormal CSF findings

102 (64.2%)

8 (66.7%)

94 (63.9%)

1^c

 Weakly positive

8

0

8

0.004 ^b

 Positive

70

1

69

Strongly positive

81

11

70

 Negative

69/157

3

66/145

0.114 ^b

 Weakly positive

17/157

1

16/145

 Positive

58/157

6

52/145

 Strongly positive

13/157

2

11/145

 IVIG(times)

1 (0–4)

2 (1–4)

1 (0–3)

0.002 ^b

 MTP(times)

1 (0–3)

1 (0–2)

1 (0–3)

0.991 ^b

 IVIG+MTP(times)

2 (1–5)

3 (1–5)

2 (1–5)

0.037 ^b

 IVIG+MTP + RTX(times)

2 (1–8)

3 (1–8)

2 (1–8)

0.042 ^b

 Interval from onset to receive IT, days, median (IQR)

24 (4–365)

12c (7–75)

25 (4–365)

0.002 ^b

 In hospital days, median (IQR)

25 (3–400)

57.5 (15–400)

24 (3–118)

0.001 ^b

 Need of ICU

20(12.6%)

7(58.3%)

13 (8.8%)

< 0.001^c

 Good outcome (mRS = 0–2)

125/144 (86.8%)

11/12 (91.7%)

114/132 (86.4%)

1^c

 Death

12/144 (8.3%)

1/12 (8.3%)

11/132 (8.3%)

1^c

 Relapse

13/144 (9.0%)

1/12 (8.3%)

12/132 (9.1%)

1^c